Gazzard Gus, Congdon Nathan, Azuara-Blanco Augusto, Blumenthal Eytan Z, Gomelauri Ketevan, Zaliniyan Monika, Traverso Carlo E, Bracha Zohar, Dvalishvili Ana, Solberg Yoram, Belkin Michael, Samuelson Thomas W
NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, United Kingdom; Institute of Ophthalmology, University College London, London, United Kingdom.
Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom; Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China; Orbis International, New York, New York.
Ophthalmology. 2025 May 9. doi: 10.1016/j.ophtha.2025.05.004.
Effective glaucoma treatment is limited by nonadherence to medications and access to selective laser trabeculoplasty (SLT). The GLAUrious study compared automated, gonioscopy-free, noncontact, image-guided direct selective laser trabeculoplasty (DSLT) with conventional SLT in open-angle glaucoma (OAG) and ocular hypertension (OHT) to reduce intraocular pressure (IOP).
Prospective, multicenter, randomized, controlled, evaluator-masked noninferiority trial.
Participants aged ≥ 40 years with OAG or OHT, on 0-3 hypotensive medications at screening, and washout IOP of 22-35 mmHg at 14 centers.
After washout, 192 participants randomized 1:1 to DSLT (n = 99) or SLT (n = 93). Intraocular pressure was assessed before treatment and through 12 months after the procedure, with washout IOP at baseline and 6 months.
Difference between DSLT and SLT in mean IOP change from baseline to 6 months (noninferiority margin, -1.95 mmHg). Exploratory efficacy and safety outcomes were assessed over 12 months.
Of 156 participants (81.3%) without major protocol deviations analyzed at 6 months, the mean ± standard error (SE) washout IOP reduction from baseline was 5.5 ± 0.5 mmHg (-20.6%) after DSLT and 6.2 ± 0.5 mmHg (-23.6%) after SLT. The between-group difference (SLT-DSLT) in mean IOP reduction was -0.7 mmHg (95% confidence interval [CI], -2.2 to 0.8 mmHg; P = 0.09 [not significant] for noninferiority). Of 161 participants (83.9%) without major protocol deviations analyzed at 12 months, mean ± SE nonwashout IOP reduction from screening was 3.2 ± 0.4 mmHg (-12.2%) after DSLT and 3.2 ± 0.4 mmHg (-9.4%) after SLT. The between-group difference in mean IOP reduction was 0.01 mmHg (95% CI, -1.1 to 1.1 mmHg; P < 0.001 for noninferiority). Safety profiles were similar between groups, although clinically nonsignificant punctate subconjunctival hemorrhage was more frequent in the DSLT group. Ocular AEs generally were mild and resolved without intervention.
The 6-month primary end point did not achieve statistical noninferiority compared with conventional SLT. Nonetheless, DSLT was well tolerated and provided an effective reduction in IOP that was sustained for 12 months. Failure to demonstrate noninferiority does not prove inferiority; DSLT remains an effective option in the early treatment paradigm and can be considered as a first-line treatment when SLT is not readily accessible.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
青光眼的有效治疗受到药物依从性差和选择性激光小梁成形术(SLT)可及性的限制。GLAUrious研究比较了自动、免前房角镜检查、非接触、图像引导的直接选择性激光小梁成形术(DSLT)与传统SLT治疗开角型青光眼(OAG)和高眼压症(OHT)以降低眼压(IOP)的效果。
前瞻性、多中心、随机、对照、评估者盲法非劣效性试验。
年龄≥40岁、患有OAG或OHT、筛查时使用0 - 3种降压药物且14个中心的洗脱期眼压为22 - 35 mmHg的参与者。
洗脱期后,192名参与者按1:1随机分为DSLT组(n = 99)或SLT组(n = 93)。在治疗前及术后12个月评估眼压,基线和6个月时为洗脱期眼压。
DSLT与SLT从基线到6个月的平均眼压变化差值(非劣效界值为-1.95 mmHg)。在12个月内评估探索性疗效和安全性指标。
在6个月时分析的156名(81.3%)无主要方案偏差的参与者中,DSLT组从基线到洗脱期眼压平均降低5.5±0.5 mmHg(-20.6%),SLT组为6.2±0.5 mmHg(-23.6%)。平均眼压降低的组间差异(SLT - DSLT)为-0.7 mmHg(95%置信区间[CI],-2.2至0.8 mmHg;非劣效性检验P = 0.09[无统计学意义])。在12个月时分析的161名(83.9%)无主要方案偏差的参与者中,DSLT组从筛查到非洗脱期眼压平均降低3.2±0.4 mmHg(-12.2%),SLT组为3.2±0.4 mmHg(-9.4%)。平均眼压降低的组间差异为0.01 mmHg(95% CI,-1.1至1.1 mmHg;非劣效性检验P < 0.001)。两组安全性概况相似,尽管DSLT组临床意义不显著的点状结膜下出血更常见。眼部不良事件一般较轻,无需干预即可缓解。
与传统SLT相比,6个月的主要终点未达到统计学非劣效性。尽管如此,DSLT耐受性良好,能有效降低眼压并持续12个月。未能证明非劣效性并不等同于劣效性;DSLT在早期治疗模式中仍是一种有效的选择,当SLT不易获得时可考虑作为一线治疗方法。
在本文末尾的脚注和披露中可能会发现专有或商业披露信息。